2021/03/29 by Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway +41 · 4 citations
Medicine · Social Sciences · #SARS-CoV-2 and COVID-19 Research #Viral gastroenteritis research and epidemiology #Vaccine Coverage and Hesitancy
paper · pdf · doi:10.15585/mmwr.mm7013e3
openalex publication_date 2021/03/29 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
In contrast, among fully immunized (≥14 days after second dose) persons, 0.04 infections per 1,000 person-days were reported, and among partially immunized (≥14 days after first dose and before second dose) persons, 0.19 infections per 1,000 person-days were reported. Estimated mRNA vaccine effectiveness for prevention of infection, adjusted for study site, was 90% for full immunization and 80% for partial immunization. These findings indicate that authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection, regardless of symptom status, among working-age adults in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.